Zevra Therapeutics, Inc. (ZVRA)

Market Cap	478.78M
Revenue (ttm)	24.49M
Net Income (ttm)	-89.66M
Shares Out	53.38M
EPS (ttm)	-2.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	570,576
Open	9.09
Previous Close	8.97
Day's Range	8.71 - 9.27
52-Week Range	4.20 - 9.27
Beta	1.93
Analysts	Strong Buy
Price Target	21.20 (+136.34%)
Earnings Date	Nov 12, 2024

About ZVRA

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the tre...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 16, 2015
• Employees: 69
• Stock Exchange: NASDAQ
• Ticker Symbol: ZVRA
• Website: https://zevra.com

Financial Performance

In 2023, Zevra Therapeutics's revenue was $27.46 million, an increase of 170.26% compared to the previous year's $10.16 million. Losses were -$46.05 million, 72.0% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for ZVRA stock is "Strong Buy." The 12-month stock price forecast is $21.2, which is an increase of 136.34% from the latest price.

Price Target

$21.2

(136.34% upside)

Analyst Consensus: Strong Buy